Atrial fibrillation laboratory findings
 |
Resident Survival Guide |
| File:Critical Pathways.gif |
Sinus rhythm  |
Atrial fibrillation  |
|
Atrial Fibrillation Microchapters | |
|
Special Groups | |
|---|---|
|
Diagnosis | |
|
Treatment | |
|
Cardioversion | |
|
Anticoagulation | |
|
Surgery | |
|
Case Studies | |
|
Atrial fibrillation laboratory findings On the Web | |
|
Directions to Hospitals Treating Atrial fibrillation laboratory findings | |
|
Risk calculators and risk factors for Atrial fibrillation laboratory findings | |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Anahita Deylamsalehi, M.D.[2]
Overview
Many cases of AF have no definite cause, it may be the result of various other problems (blood tests of thyroid function are required, especially for a first episode of AF, when the ventricular rate is difficult to control, or when AF recurs unexpectedly after cardioversion).
Laboratory Findings
- Renal function and electrolytes are routinely performed in patients suffering from atrial fibrillation.
- Thyroid function tests : Thyroid-stimulating hormone (TSH) is commonly suppressed in hyperthyroidism and of relevance if amiodarone is administered for treatment.[1]
- Complete blood count
- Cardiac markers : In acute-onset AF associated with chest pain, cardiac troponins or other markers of damage to the heart muscle may be ordered.
- Coagulation studies (INR/aPTT) are usually performed, as anticoagulant medication may be commenced.
- High sensitivity C-reactive protein (hs-CRP) could act as a predictive marker for cardiac related complications and death.[2][3]
- It is recommended to calculate time in therapeutic range (TTR) for patients who are under treatment for atrial fibrillation.[4]
- Based on NICE guideline usage of a sound method such as the Rosendaal method is recommended.
- It is recommended to exclude measures of the first 6 weeks of treatment.
- Time in therapeutic range (TTR) is more trusted if it is calculated over at least 6 months of a period.
References
- ↑ Krahn AD, Klein GJ, Kerr CR, Boone J, Sheldon R, Green M; et al. (1996). "How useful is thyroid function testing in patients with recent-onset atrial fibrillation? The Canadian Registry of Atrial Fibrillation Investigators". Arch Intern Med. 156 (19): 2221–4. PMID 8885821.
- ↑ Hermida J, Lopez FL, Montes R, Matsushita K, Astor BC, Alonso A (2012). "Usefulness of high-sensitivity C-reactive protein to predict mortality in patients with atrial fibrillation (from the Atherosclerosis Risk In Communities [ARIC] Study)". Am J Cardiol. 109 (1): 95–9. doi:10.1016/j.amjcard.2011.08.010. PMC 4062871. PMID 21962993.
- ↑ Ridker PM (2001). "High-sensitivity C-reactive protein: potential adjunct for global risk assessment in the primary prevention of cardiovascular disease". Circulation. 103 (13): 1813–8. doi:10.1161/01.cir.103.13.1813. PMID 11282915.
- ↑ Perry M, Kemmis Betty S, Downes N, Andrews N, Mackenzie S, Guideline Committee (2021). "Atrial fibrillation: diagnosis and management-summary of NICE guidance". BMJ. 373: n1150. doi:10.1136/bmj.n1150. PMID 34020968 Check
|pmid=value (help).